Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05548010
Other study ID # VTE
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 29, 2022
Est. completion date November 29, 2023

Study information

Verified date March 2023
Source Chinese University of Hong Kong
Contact Daniel Xu
Phone 35051518
Email danielxu@cuhk.edu.hk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Venous thromboembolism (VTE) is common especially among post-operative patients, and its occurrence is associated with significant morbidity and mortality. VTE is highly preventable with prophylactic modalities ranging from conservative measures such as early mobilization, to mechanical prophylaxis such as intermittent pneumatic compression (ICP), to pharmacological prophylaxis such as peri-operative anticoagulation. Despite established guidelines from various professional societies, the practice of VTE prophylaxis varied greatly from institute to institute. Evidence suggests that there is a significant gap between the optimal thromboprophylaxis as suggested by experts and real-work practice. Many healthcare-providers (HCP) and patients at risk of VTE are either not aware of the risk of VTE or not confident to apply the necessary thromboprophylaxis. The knowledge level of VTE appears to play a key role in affecting the level of compliance to the optimal thromboprophylaxis. Considerable improvement in VTE prophylaxis utilization may result from the implementation of a multifaceted educational program. By improving patient's awareness on VTE prophylaxis, the incidence of DVT might be reduced. The knowledge level of patients can be improved by various means including educational video, administrative measures, or continue medical education program. However, no prospective study has been performed to assess the impact of an educational program on the VTE knowledge level among post-operative patients and their HCP, and if any improvement of their knowledge level can be translated to a better adherence to VTE prophylaxis guidelines. We therefore propose to conduct a prospective non-randomized controlled study to evaluate the effect of an education materials for the patients as well as their HCP on their knowledge level as well as the utilization and adherence of VTE prophylaxis in these patients by comparing two groups of patients and HCP.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date November 29, 2023
Est. primary completion date November 29, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Capable of providing written informed consent and willing and able to adhere to all protocol requirements - Male or female at least 18 years of age at the time of providing written informed consent - Adult patients age >18 scheduled for surgical operations - Healthcare Providers directedly involve in patients care of these surgical patients. Exclusion criteria - Unable to make their own informed consent - Unable to understand the study protocol - Visually or auditorily impaired.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention as this is an observational study
No intervention

Locations

Country Name City State
Hong Kong The Chinese University of Hong Kong Shatin

Sponsors (1)

Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in VTE knowledge between 2 groups Difference between the knowledge level in the subject group and HCP group after the administration of the educational materials as measured with questionnaire 4 weeks
Primary VTE prophylaxis prescription by healthcare providers Difference in VTE prophylaxis prescribed by HCP after the administration of the educational materials assessed upon patient follow-up/ discharge as reflected by drug prescription sheet and discharge summary 4 weeks
Primary VTE prophylaxis adherence VTE prophylaxis will be advised to subjects upon discharge. Difference in VTE prophylaxis adherence of subjects after the administration of the educational materials will be assessed verbally during follow-up consultation by investigators. 4 weeks
Secondary Difference in VTE knowledge level within the HCP group difference in VTE knowledge level within the HCP group before and after the administration of the educational materials as measured with questionnaire. 4 weeks
Secondary Difference in patient satisfaction Difference in patient satisfaction scoring before and after the administration of the educational materials to the HCPs assessed during patient follow-up consultation by investigators 4 weeks
Secondary Difference in the rate of venous thromboembolism (VTE) Difference in rate of VTE in the HCP group before and after the administration of the educational materials. 4 weeks
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Active, not recruiting NCT05563883 - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Terminated NCT02475187 - Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
Recruiting NCT00982514 - Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 N/A
Completed NCT01420809 - Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection N/A
Terminated NCT00206089 - Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events Phase 3
Completed NCT00014352 - Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Phase 2
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Completed NCT02935751 - Apixaban Discontinuation Prior to Major Surgery
Terminated NCT02579122 - REVIparin-BRIDging-in a General Practice Setting in GErmany
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Terminated NCT00662688 - Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer Phase 3
Completed NCT00260988 - A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery Phase 2/Phase 3
Terminated NCT00031837 - Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Phase 3
Completed NCT03877770 - DVT After Cardiac Procedure
Completed NCT00024297 - Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters N/A
Recruiting NCT06118957 - Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery Phase 2